A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: serious (676), severe (726), grave (12), critical (189), acute (409)

Papers Council of Governors - 27 April 2022

Description
Date Time Location Chair Agenda Council of Governors 27/04/2022 14:00 - 16:00 Microsoft Teams Jane Bailey 1 Chair
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-27-April-2022.pdf

Laboratory medicine user handbook rev 22

Description
University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.7 Laboratory Medicine user handbook rev 22 G3.7 Laboratory Medicine Laboratory
Url
/Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Laboratory-medicine-user-handbook.pdf

Chimeric antigen receptor T-cell (CAR-T) therapy discharge medicines - patient information

Description
This factsheet explains what chimeric antigen receptor T-cell (CAR-T) therapy is and what it involves so you know what
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Chimeric-antigen-receptor-T-cell-CAR-T-therapy-discharge-meds-3635-PIL.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Indication • Obinutuzumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf

O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine (O-CHOP) Regimen • NHL – O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-PrednisoloneVincristine Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine.pdf

InP-MATRix

Description
Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabine-Methotrexate-Rituximab-Thiotepa Indication • Non-Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf

Bendamustine-Polatuzumab-Rituximab

Description
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB-RITUXIMAB Regimen • Lymphoma – Bendamustine-Polatuzumab-Rituximab Indication • Histologically diagnosed diffuse large B cell lymphoma (DLBCL) including
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Polatuzumab-Rituximab.pdf

Bendamustine-Obinutuzumab

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description
Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib (twice weekly) with daratumumab and dexamethasone Note
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf
91 to 100 of 518
Previous … 8 9 10 11 12 … Next